Furthermore, as HSP90 inhibitors were shown to modulate several MAP kinases involved in inflammation, cell proliferation and fibrogenesis, further studies are needed to define in particular these pathways in IPF. The gene discussed is HSP90AA1; the disease is idiopathic pulmonary fibrosis.